This, as well as the previously demonstrated ability of heparin to interfere with the ACE2/S glycoprotein association [9,10], indicates that this century-old therapeutic can act as an effective and multi-prong antiviral agent, providing a rationale behind the apparent clinical success of this drug in the COVID-19 setting [48]. Here, ACE2 is linked to COVID-19.